ArticleFrontiers in oncology2026
Distribution and clinical significance of peripheral blood lymphocyte PD-1 and PD-L1 in non-Hodgkin lymphoma: a retrospective study in Chinese patients.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Programmed death-1 (PD-1) and its ligand PD-L1 play critical roles in immune checkpoint regulation. This study investigated the relationship between PD-1 and PD-L1 expression on peripheral blood lymphocytes and Non- Hodgkin Lymphoma progression. Methods: This retrospective study included patients diagnosed with Non- Hodgkin Lymphoma at Jilin Cancer Hospital between October 2013 and May 2017. PD-1 and PD-L1 expression on CD4+ and CD8+ T cells was analyzed using flow cytometry. Results: A total of 125 non- Hodgkin Lymphoma patients (65 males and 60 females; median age, 57 years; range, 14-86 years) were included. PD-1 and PD-L1 expression on CD8+ T cells was significantly higher in patients with elevated lactate dehydrogenase (LDH) (>245 U/L) than in those with normal LDH (PD-1: 16.46% Conclusion: Peripheral blood lymphocyte PD-1 and PD-L1 expression are associated with LDH levels, bone marrow involvement, and treatment response. A reduction in CD4+ PD-1 levels after treatment is associated with a trend towards improved overall survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.